Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28094255 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL7680971 | 0.89 | CYP3A4 (0.67) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP3A4 | |
| Diphenylmethanol SCHEMBL6434457 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4ECYP2D6LMNAL3MBTL1 | |
| Diphenylmethanol SCHEMBL10868602 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4ECYP2D6LMNAL3MBTL1 | |
| Diphenylmethanol SCHEMBL41571 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4ECYP2D6LMNAL3MBTL1 | |
| Diphenylmethanol SCHEMBL11564700 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4ECYP2D6LMNAL3MBTL1 | |
| SCHEMBL18228789 | 0.82 | SMN1; SMN2 (0.81) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL11605458 | 0.82 | SRD5A2 (0.62) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP3A4 | |
| Diphenylmethanol SCHEMBL15641329 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4ECYP2D6LMNAL3MBTL1 | |
| Diphenylmethanol SCHEMBL9324200 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4ECYP2D6LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0301403-B1 | CURING AGENT FOR SYNTHETIC RESINS, COMPOSITIONS CONTAINING THE SAME AND USES OF THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-15 | — | — | EP | claimed |
| US-4847346-A | HYDROXYALKYLPYRIDINE BLOCKED DIISOCYANATES AS CURING AGENTS | HOECHST AG (DE) | 1989-07-11 | — | — | US | claimed |
| EP-0301403-A2 | Curing agent for synthetic resins, compositions containing the same and uses of them | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-01 | — | — | EP | claimed |
| CN-108368081-B | Andrographolide modified compound | 黑龙江珍宝岛药业股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-109422771-B | Hydrothermally stable anion pillared hybrid porous material and preparation method and application thereof | 浙江大学 | 2020-07-24 | — | — | CN | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| CN-109678789-A | A method of regulating and controlling pyridine derivate catalytic hydrogenation reaction using oxidation-reduction potential | 安徽德信佳生物医药有限公司 | 2019-04-26 | — | — | CN | disclosed |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | MEDSHINE DISCOVERY INC. (CN) | 2018-12-06 | — | — | US | disclosed |
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120129870-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| WO-1992019596-A2 | PROCESSES FOR PRODUCING α-PYRIDYL CARBINOLS | REILLY INDUSTRIES, INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0301403-B1 | CURING AGENT FOR SYNTHETIC RESINS, COMPOSITIONS CONTAINING THE SAME AND USES OF THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-15 | — | — | EP | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4847346-A | HYDROXYALKYLPYRIDINE BLOCKED DIISOCYANATES AS CURING AGENTS | HOECHST AG (DE) | 1989-07-11 | — | — | US | disclosed |
| EP-0301403-A2 | Curing agent for synthetic resins, compositions containing the same and uses of them | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-01 | — | — | EP | disclosed |
| US-4098908-A | PHENOXYPHENYL PYRIDYL KETONES AND DERIVATIVES AND THEIR USE AS HYPOLEPIDEMIC AGENTS | SANDOZ, INC. (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129870-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | SMN1; SMN2 3545/4885SLC6A2 1138/4885SLC6A4 1640/4885 |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | SMN1; SMN2 4362/4885SLC6A2 3969/4885SLC6A4 2886/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | SMN1; SMN2 3845/4885SLC6A2 1596/4885SLC6A4 2222/4885 |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | CYP11B2, CYP11B1, DUSP23 | SMN1; SMN2 3845/4885SLC6A2 1596/4885SLC6A4 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.